National Institute of Neurological Disorders and Stroke

Walter J. Koroshetz, Director of NINDS since 2015, oversees the institute's scientific priorities and budget allocation, while the National Advisory Neurological Disorders and Stroke Council — a panel of scientists, clinicians, and public members — reviews and approves grant funding based on peer-review scores (per NINDS organizational chart, 2023).

NINDS exclusively issues grants and cooperative agreements — it does not take equity, royalties, or ownership stakes in commercial entities. Its funding mechanism is purely philanthropic, with no return requirement, although patent rights from funded research may revert to institutions under the Bayh-Dole Act.

NINDS awards grants primarily on investigator-initiated proposals, meaning researchers from universities and medical centers submit ideas through the NIH grant system. The institute also funds targeted initiatives through Requests for Applications in areas like stroke recovery or gene therapy for neurological disorders (per NINDS funding strategy, 2024).

NINDS funds basic science, translational research, and clinical trials — from discovery through Phase 3 studies. It does not fund late-stage drug development or manufacturing, which is left to industry and venture capital. The institute also supports early-stage small businesses through its SBIR and STTR programs.

NINDS avoids funding non-neurologic conditions — it focuses exclusively on the brain, spinal cord, peripheral nerves, and neuromuscular disorders. It also does not fund laboratory equipment construction, medical care, or drug marketing, and will not fund for-profit drug production or sales operations.

NINDS operates as a separate institute within the NIH, coordinating with the National Institute of Mental Health, National Eye Institute, and National Institute on Aging on shared neurologic and psychiatric research. It also participates in cross-NIH initiatives like the BRAIN Initiative and the NIH HEAL Initiative (per NINDS partnership page, 2024).

NINDS receives its entire budget from congressional appropriations — not private donations, endowment, or investment returns. For fiscal year 2025, the U.S. government allocated approximately $2.5B, making NINDS one of the largest single public-funding sources for neurological research globally (per NIH Office of Budget, 2025).